Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction.

Clusters Comorbidities External validation Heart failure with preserved ejection fraction Latent class analysis Phenotyping Treatment

Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
06 2021
Historique:
revised: 22 03 2021
received: 18 11 2020
accepted: 23 03 2021
pubmed: 30 3 2021
medline: 11 8 2021
entrez: 29 3 2021
Statut: ppublish

Résumé

We aimed to derive and validate clinically useful clusters of patients with heart failure with preserved ejection fraction (HFpEF; left ventricular ejection fraction ≥50%). We derived a cluster model from 6909 HFpEF patients from the Swedish Heart Failure Registry (SwedeHF) and externally validated this in 2153 patients from the Chronic Heart Failure ESC-guideline based Cardiology practice Quality project (CHECK-HF) registry. In SwedeHF, the median age was 80 [interquartile range 72-86] years, 52% of patients were female and most frequent comorbidities were hypertension (82%), atrial fibrillation (68%), and ischaemic heart disease (48%). Latent class analysis identified five distinct clusters: cluster 1 (10% of patients) were young patients with a low comorbidity burden and the highest proportion of implantable devices; cluster 2 (30%) patients had atrial fibrillation, hypertension without diabetes; cluster 3 (25%) patients were the oldest with many cardiovascular comorbidities and hypertension; cluster 4 (15%) patients had obesity, diabetes and hypertension; and cluster 5 (20%) patients were older with ischaemic heart disease, hypertension and renal failure and were most frequently prescribed diuretics. The clusters were reproduced in the CHECK-HF cohort. Patients in cluster 1 had the best prognosis, while patients in clusters 3 and 5 had the worst age- and sex-adjusted prognosis. Five distinct clusters of HFpEF patients were identified that differed in clinical characteristics, heart failure drug therapy and prognosis. These results confirm the heterogeneity of HFpEF and form a basis for tailoring trial design to individualized drug therapy in HFpEF patients.

Identifiants

pubmed: 33779119
doi: 10.1002/ejhf.2169
pmc: PMC8359985
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

973-982

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

JAMA. 2016 Jan 5;315(1):36-46
pubmed: 26746456
Circulation. 2011 May 10;123(18):2006-13; discussion 2014
pubmed: 21555723
Eur J Heart Fail. 2020 Jan;22(1):103-112
pubmed: 31478583
Eur Heart J. 2016 Feb 1;37(5):455-62
pubmed: 26374849
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Circulation. 2015 Jan 20;131(3):269-79
pubmed: 25398313
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Heart Fail. 2015 Sep;17(9):925-35
pubmed: 26250359
Heart. 2020 Mar;106(5):342-349
pubmed: 31911501
Neth Heart J. 2018 May;26(5):272-279
pubmed: 29564639
PLoS Med. 2019 Sep 24;16(9):e1002916
pubmed: 31550265
Eur J Heart Fail. 2018 Mar;20(3):431-432
pubmed: 29333631
Ups J Med Sci. 2019 Jan;124(1):65-69
pubmed: 30092697
Nat Rev Cardiol. 2020 Sep;17(9):559-573
pubmed: 32231333
Eur J Heart Fail. 2018 Aug;20(8):1230-1239
pubmed: 29431256
Heart Fail Clin. 2014 Jul;10(3):407-18
pubmed: 24975905
J Am Soc Echocardiogr. 2019 May;32(5):604-615.e6
pubmed: 30718020
Eur Heart J. 2018 Dec 21;39(48):4257-4265
pubmed: 30351407
Circulation. 2013 Sep 3;128(10):1085-93
pubmed: 23908348
Circulation. 2017 Jul 4;136(1):6-19
pubmed: 28381470
Eur Heart J. 2018 Jan 1;39(1):26-35
pubmed: 29040525
Int J Cardiol. 2019 Feb 15;277:140-146
pubmed: 30131230
JACC Heart Fail. 2020 Mar;8(3):172-184
pubmed: 31926856
Eur J Heart Fail. 2020 Jan;22(1):148-158
pubmed: 31637815
Arch Cardiovasc Dis. 2020 Jun - Jul;113(6-7):381-390
pubmed: 32409103

Auteurs

Alicia Uijl (A)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Gianluigi Savarese (G)

Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Ilonca Vaartjes (I)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Ulf Dahlström (U)

Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linkoping University, Linköping, Sweden.

Jasper J Brugts (JJ)

Department of Cardiology, Thoraxcenter, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Gerard C M Linssen (GCM)

Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands.

Vanessa van Empel (V)

Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.

Hans-Peter Brunner-La Rocca (HP)

Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.

Folkert W Asselbergs (FW)

Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Health Data Research UK London, Institute for Health Informatics, University College London, London, UK.
Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK.

Lars H Lund (LH)

Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.

Arno W Hoes (AW)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Stefan Koudstaal (S)

Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Department of Cardiology, Groene Hart Ziekenhuis, Gouda, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH